_id

690da8efccc777a4e85d0813

Ticker

ACIU

Name

AC Immune Ltd

Exchange

NASDAQ

Address

Building B, Lausanne, Switzerland, 1015

Country

USA

Sector

Healthcare

Industry

Biotechnology

Currency

USD

Website

https://www.acimmune.com

Description

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Last Close

2.79

Volume

159746

Current Price

3.22

Change

15.412186379928322

Last Updated

2025-11-28T11:47:49.004Z

Image

-

Ipo Date

2016-09-23T00:00:00.000Z

Market Cap

294758016

Next Dividend Date

-

Dividend Frequency

-

Dividend Rate

-

Dividend Yield

0

Sentiment

0.995

Sentiment Sources

1

Rating

4.75

Target Price

9.7152

Strong Buy

3

Buy

1

Hold

0

Sell

0

Strong Sell

0

Current Quarter

2025-09-30

Revenue

939000

Cost Of Revenue

-

Gross Profit

939000

Operating Expenses

17105000

Operating Income

-16166000

Interest Expense

46000

Pretax Income

-15858000

Net Income

-15858000

Eps

-0.16

Dividends Per Share

-

Shares Outstanding

100600000

Income Tax Expense

-

EBITDA

-15518000

Operating Margin

-1721.6187433439832

Total Other Income Expense Net

308000

Cash

27741000

Short Term Investments

80727000

Receivables

402000

Inventories

-

Total Current Assets

113746000

Property Plant Equipment

6861000

Total Assets

171607000

Payables

1566000

Short Term Debt

1044999

Long Term Debt

-

Total Liabilities

109163000

Equity

62444000

Depreciation

613000

Change In Working Capital

-99000

Cash From Operations

-18340000

Capital Expenditures

58000

Cash From Investing

20628000

Cash From Financing

-254000

Net Change In Cash

2019000

PE

-

PB

5.11085532637243

ROE

-25.395554416757417

ROA

-9.24088178221168

FCF

-18398000

Fcf Percent

-19.59318423855165

Piotroski FScore

0

Health Score

19

Deep Value Investing Score

2

Defensive Investing Score

5.5

Dividend Investing Score

1.5

Economic Moat Investing Score

3.8

Garp Investing Score

1.5

Growth Investing Score

1

Momentum Investing Score

3

Net Net Investing Score

2.5

Quality Investing Score

2

Value Investing Score

2.5

Quarters > 0 > quarter

2025-09-30

Quarters > 0 > income Statement > revenue

939000

Quarters > 0 > income Statement > cost Of Revenue

-

Quarters > 0 > income Statement > gross Profit

939000

Quarters > 0 > income Statement > operating Expenses

17105000

Quarters > 0 > income Statement > operating Income

-16166000

Quarters > 0 > income Statement > interest Expense

46000

Quarters > 0 > income Statement > pretax Income

-15858000

Quarters > 0 > income Statement > net Income

-15858000

Quarters > 0 > income Statement > eps

-0.16

Quarters > 0 > income Statement > dividends Per Share

-

Quarters > 0 > income Statement > shares Outstanding

99112500

Quarters > 0 > income Statement > income Tax Expense

-

Quarters > 0 > income Statement > EBITDA

-15518000

Quarters > 0 > income Statement > operating Margin

-1721.6187433439832

Quarters > 0 > income Statement > total Other Income Expense Net

308000

Quarters > 0 > balance Sheet > cash

27741000

Quarters > 0 > balance Sheet > short Term Investments

80727000

Quarters > 0 > balance Sheet > receivables

402000

Quarters > 0 > balance Sheet > inventories

-

Quarters > 0 > balance Sheet > total Current Assets

113746000

Quarters > 0 > balance Sheet > property Plant Equipment

6861000

Quarters > 0 > balance Sheet > total Assets

171607000

Quarters > 0 > balance Sheet > payables

1566000

Quarters > 0 > balance Sheet > short Term Debt

1044999

Quarters > 0 > balance Sheet > long Term Debt

-

Quarters > 0 > balance Sheet > total Liabilities

109163000

Quarters > 0 > balance Sheet > equity

62444000

Quarters > 0 > cash Flow > net Income

-15858000

Quarters > 0 > cash Flow > depreciation

613000

Quarters > 0 > cash Flow > change In Working Capital

-99000

Quarters > 0 > cash Flow > cash From Operations

-18340000

Quarters > 0 > cash Flow > capital Expenditures

58000

Quarters > 0 > cash Flow > cash From Investing

20628000

Quarters > 0 > cash Flow > cash From Financing

-254000

Quarters > 0 > cash Flow > net Change In Cash

2019000

Quarters > 0 > ratios > PE

-0.16

Quarters > 0 > ratios > PB

5.11085532637243

Quarters > 0 > ratios > ROE

-25.395554416757417

Quarters > 0 > ratios > ROA

-9.24088178221168

Quarters > 0 > ratios > FCF

-18398000

Quarters > 0 > ratios > Piotroski FScore

0

Quarters > 0 > ratios > fcf Percent

-19.59318423855165

Quarters > 0 > health Score

19

Quarters > 1 > quarter

2025-06-30

Quarters > 1 > income Statement > revenue

1306000

Quarters > 1 > income Statement > cost Of Revenue

-

Quarters > 1 > income Statement > gross Profit

1306000

Quarters > 1 > income Statement > operating Expenses

20694000

Quarters > 1 > income Statement > operating Income

-19388000

Quarters > 1 > income Statement > interest Expense

50000

Quarters > 1 > income Statement > pretax Income

-21189000

Quarters > 1 > income Statement > net Income

-21189000

Quarters > 1 > income Statement > eps

-0.2105605815506578

Quarters > 1 > income Statement > dividends Per Share

-

Quarters > 1 > income Statement > shares Outstanding

100631371

Quarters > 1 > income Statement > income Tax Expense

-

Quarters > 1 > income Statement > EBITDA

-20516000

Quarters > 1 > income Statement > operating Margin

-1484.5329249617153

Quarters > 1 > income Statement > total Other Income Expense Net

-1801000

Quarters > 1 > balance Sheet > cash

25722000

Quarters > 1 > balance Sheet > short Term Investments

101413000

Quarters > 1 > balance Sheet > receivables

2131000

Quarters > 1 > balance Sheet > inventories

-

Quarters > 1 > balance Sheet > total Current Assets

131808000

Quarters > 1 > balance Sheet > property Plant Equipment

7416000

Quarters > 1 > balance Sheet > total Assets

190224000

Quarters > 1 > balance Sheet > payables

2729000

Quarters > 1 > balance Sheet > short Term Debt

1039000

Quarters > 1 > balance Sheet > long Term Debt

-

Quarters > 1 > balance Sheet > total Liabilities

115481000

Quarters > 1 > balance Sheet > equity

74743000

Quarters > 1 > cash Flow > net Income

-21189000

Quarters > 1 > cash Flow > depreciation

623000

Quarters > 1 > cash Flow > change In Working Capital

2213000

Quarters > 1 > cash Flow > cash From Operations

-15598000

Quarters > 1 > cash Flow > capital Expenditures

373000

Quarters > 1 > cash Flow > cash From Investing

23883000

Quarters > 1 > cash Flow > cash From Financing

-247000

Quarters > 1 > cash Flow > net Change In Cash

5762000

Quarters > 1 > ratios > PE

-0.2105605815506578

Quarters > 1 > ratios > PB

4.335295808570703

Quarters > 1 > ratios > ROE

-28.34914306356448

Quarters > 1 > ratios > ROA

-11.138973000252333

Quarters > 1 > ratios > FCF

-15971000

Quarters > 1 > ratios > Piotroski FScore

1

Quarters > 1 > ratios > fcf Percent

-12.228943338437979

Quarters > 1 > health Score

20

Quarters > 2 > quarter

2025-03-31

Quarters > 2 > income Statement > revenue

990000

Quarters > 2 > income Statement > cost Of Revenue

-

Quarters > 2 > income Statement > gross Profit

990000

Quarters > 2 > income Statement > operating Expenses

20360000

Quarters > 2 > income Statement > operating Income

-19370000

Quarters > 2 > income Statement > interest Expense

54000

Quarters > 2 > income Statement > pretax Income

-19029000

Quarters > 2 > income Statement > net Income

-19029000

Quarters > 2 > income Statement > eps

-0.18951530124671667

Quarters > 2 > income Statement > dividends Per Share

-

Quarters > 2 > income Statement > shares Outstanding

100408779

Quarters > 2 > income Statement > income Tax Expense

-

Quarters > 2 > income Statement > EBITDA

-18363000

Quarters > 2 > income Statement > operating Margin

-1956.5656565656564

Quarters > 2 > income Statement > total Other Income Expense Net

341000

Quarters > 2 > balance Sheet > cash

19960000

Quarters > 2 > balance Sheet > short Term Investments

125654000

Quarters > 2 > balance Sheet > receivables

2913000

Quarters > 2 > balance Sheet > inventories

-

Quarters > 2 > balance Sheet > total Current Assets

152134000

Quarters > 2 > balance Sheet > property Plant Equipment

7947000

Quarters > 2 > balance Sheet > total Assets

211082000

Quarters > 2 > balance Sheet > payables

2391000

Quarters > 2 > balance Sheet > short Term Debt

1033000

Quarters > 2 > balance Sheet > long Term Debt

-

Quarters > 2 > balance Sheet > total Liabilities

116284000

Quarters > 2 > balance Sheet > equity

94798000

Quarters > 2 > cash Flow > net Income

-19029000

Quarters > 2 > cash Flow > depreciation

612000

Quarters > 2 > cash Flow > change In Working Capital

-2296000

Quarters > 2 > cash Flow > cash From Operations

-18816000

Quarters > 2 > cash Flow > capital Expenditures

362000

Quarters > 2 > cash Flow > cash From Investing

3028000

Quarters > 2 > cash Flow > cash From Financing

-258000

Quarters > 2 > cash Flow > net Change In Cash

-16315000

Quarters > 2 > ratios > PE

-0.18951530124671667

Quarters > 2 > ratios > PB

3.410581113314627

Quarters > 2 > ratios > ROE

-20.07320829553366

Quarters > 2 > ratios > ROA

-9.014979960394538

Quarters > 2 > ratios > FCF

-19178000

Quarters > 2 > ratios > Piotroski FScore

1

Quarters > 2 > ratios > fcf Percent

-19.371717171717172

Quarters > 2 > health Score

20

Quarters > 3 > quarter

2024-12-31

Quarters > 3 > income Statement > revenue

1137000

Quarters > 3 > income Statement > cost Of Revenue

-

Quarters > 3 > income Statement > gross Profit

1137000

Quarters > 3 > income Statement > operating Expenses

19755000

Quarters > 3 > income Statement > operating Income

-18618000

Quarters > 3 > income Statement > interest Expense

30000

Quarters > 3 > income Statement > pretax Income

-15794000

Quarters > 3 > income Statement > net Income

-15797000

Quarters > 3 > income Statement > eps

-0.15662468169406968

Quarters > 3 > income Statement > dividends Per Share

-

Quarters > 3 > income Statement > shares Outstanding

100858944

Quarters > 3 > income Statement > income Tax Expense

3000

Quarters > 3 > income Statement > EBITDA

-15235000

Quarters > 3 > income Statement > operating Margin

-1637.467018469657

Quarters > 3 > income Statement > total Other Income Expense Net

2824000

Quarters > 3 > balance Sheet > cash

36275000

Quarters > 3 > balance Sheet > short Term Investments

129214000

Quarters > 3 > balance Sheet > receivables

1099000

Quarters > 3 > balance Sheet > inventories

-

Quarters > 3 > balance Sheet > total Current Assets

171994000

Quarters > 3 > balance Sheet > property Plant Equipment

8087999

Quarters > 3 > balance Sheet > total Assets

230913000

Quarters > 3 > balance Sheet > payables

2658000

Quarters > 3 > balance Sheet > short Term Debt

1026000

Quarters > 3 > balance Sheet > long Term Debt

-

Quarters > 3 > balance Sheet > total Liabilities

118643000

Quarters > 3 > balance Sheet > equity

112270000

Quarters > 3 > cash Flow > net Income

-15797000

Quarters > 3 > cash Flow > depreciation

529000

Quarters > 3 > cash Flow > change In Working Capital

22360000

Quarters > 3 > cash Flow > cash From Operations

5934000

Quarters > 3 > cash Flow > capital Expenditures

90000

Quarters > 3 > cash Flow > cash From Investing

-3826000

Quarters > 3 > cash Flow > cash From Financing

-197000

Quarters > 3 > cash Flow > net Change In Cash

3858000

Quarters > 3 > ratios > PE

-0.15662468169406968

Quarters > 3 > ratios > PB

2.8927211158813573

Quarters > 3 > ratios > ROE

-14.070544223746326

Quarters > 3 > ratios > ROA

-6.8411046584644435

Quarters > 3 > ratios > FCF

5844000

Quarters > 3 > ratios > Piotroski FScore

2

Quarters > 3 > ratios > fcf Percent

5.139841688654354

Quarters > 3 > health Score

44

Valuation > metrics > PE

-0.16

Valuation > metrics > PB

5.11085532637243

Valuation > final Score

28.891446736275697

Valuation > verdict

70.4% Overvalued

Profitability > metrics > ROE

-25.395554416757417

Profitability > metrics > ROA

-13.941589154783465

Profitability > metrics > Net Margin

-16.88817891373802

Profitability > final Score

0

Profitability > verdict

Weak

Risk > metrics > Debt Equity

1.7481743642303504

Risk > metrics > Interest Coverage

-351.4347826086956

Risk > final Score

-1376

Risk > verdict

High

Liquidity > metrics > Current Ratio

43.56416835088792

Liquidity > metrics > Quick Ratio

43.56416835088792

Liquidity > final Score

100

Liquidity > verdict

Great

Prev Valuations > 0

36.64704191429297

Prev Valuations > 1

45.89418886685373

Prev Valuations > 2

80

Prev Profitabilities > 0

0

Prev Profitabilities > 1

0

Prev Profitabilities > 2

0

Prev Risks > 0

-1521

Prev Risks > 1

-1405

Prev Risks > 2

-2452

Prev Liquidities > 0

100

Prev Liquidities > 1

100

Prev Liquidities > 2

100

Updated At

2025-12-13T00:23:24.857Z